TRVI View GSK's decision to halt camlipixant in RCC as a positive for TRVI, ending the P2X3 class and leaving Haduvio the leading differenti
TRVI View GSK's decision to halt camlipixant in RCC as a positive for TRVI, ending the P2X3 class and leaving Haduvio the leading differentiated candidate; Briley reiterate Buy and raise PT to $31 from $21 @ Briley
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.